Related Experiment Video
Updated: May 8, 2026
08:38
A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
Published on: July 21, 2023
Neonatal transplant in hypoxic injury
1Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Methods in Molecular Biology (Clifton, N.J.)
|August 13, 2013
Summary
Stem cell therapy shows promise for treating neonatal hypoxic-ischemic encephalopathy (HIE). Neurogenic astrocytes can be cultured and transplanted to potentially replace damaged neurons in HIE models.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Neonatal Research
Background:
- Hypoxic-ischemic encephalopathy (HIE) in newborns frequently leads to lifelong neurological impairments.
- Current treatments for HIE are limited, highlighting the need for novel therapeutic strategies.
- Stem cell therapy offers a potential avenue for treating HIE-related brain damage.
Purpose of the Study:
- To investigate the potential of neurogenic astrocytes as a cell replacement therapy for HIE.
- To describe methods for generating and culturing these astrocytes.
- To outline protocols for transplanting astrocytes into HIE animal models.
Main Methods:
- Generation of a hypoxic-ischemic encephalopathy (HIE) animal model.
- Culturing of neurogenic astrocytes with neural stem cell (NSC) characteristics as adherent monolayers.
- Transplantation of cultured astrocytes into neonatal and adult HIE animal models.
Main Results:
- Neurogenic astrocytes can be successfully cultured and maintained.
- These astrocytes demonstrate the capacity to generate neuronal progeny both in vitro and in vivo.
- The study outlines procedures for assessing donor cell engraftment, survival, and integration in HIE models.
Conclusions:
- Neurogenic astrocytes are promising candidates for cell replacement therapy in HIE.
- Optimized protocols for cell cultivation and rigorous testing are essential for successful transplantation.
- This research provides a framework for developing cell-based treatments for HIE.
